Bronchial Hyperreactivity in Children With Crohn Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01297907

Enrollment

Registered

2011-02-17

Start date

2008-05-31

Completion date

2009-12-31

Last updated

2011-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Keywords

Crohn's Disease, Bronchial hyper reactivity, Fractional exhaled NO, Methacholine Challenge Test, Pediatric Crohn's Disease Activity Index, To determine the frequency of bronchial hyperreactivity in pediatric patients followed and treated for Crohn disease

Brief summary

Background: Latent pulmonary involvement is described in Crohn Disease(CD). Bronchial hyperreactivity measured by the Methacholine Challenge Test (MCT) has been evaluated in two studies involving mainly adults.Our aim was to determine the frequency of bronchial hyperreactivity in pediatric patients followed and treated for Crohn disease. Methods: Twenty-three children with Crohn disease completed a questionnaire, followed by spirometry, Methacholine Challenge Test (MCT) and determination of Fractional Exhaled NO (FENO). The control group included patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT).

Interventions

OTHERMethacholine Challenge Test

Methacholine challenge test to evaluate airway hyperreactivity

OTHERFractional Exhaled NO (FENO)

Fractional Exhaled NO to evaluate eosinophilic inflammation

OTHERBlood Test

Blood Tests (Eosinophil Count)

OTHERPCDAI

Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Children with Crohn disease * Children that can perform lung function tests (MCT)

Exclusion criteria

* Upper respiratory tract infection last month * Fever or Pneumonia last month * Smoking * Other chronic diseases * Other respiratory diseases

Design outcomes

Primary

Measure	Time frame	Description
Methacholine challenge test	18 months	As assessed by methacholine challenge test with determination of PC20.

Secondary

Measure	Time frame	Description
Fractional Exhaled NO	Day 1	Exhaled NO test
Eosinophils count	Day 1	blood test
Pediatric Crohn's Disease Activity Index (PCDAI)	Day 1	Clinical Evaluation

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026